The most reported IRRs by patients self-administering agalsidase alfa were gastrointestinal disorders, affecting 3 (1.5%) patients, while the most reported IRRs in patients receiving HCP-supported infusions were general disorders and administration site conditions affecting 133 (5.5%) patients. Here, GLA is linked to digestive system disorder.